Brokerages Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $46.83

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been assigned an average recommendation of “Buy” from the ten research firms that are currently covering the company, Marketbeat reports. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $52.14.

Several research analysts have recently weighed in on DNTH shares. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim reaffirmed a “buy” rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, TD Cowen began coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating on the stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC bought a new position in shares of Dianthus Therapeutics during the third quarter valued at about $556,000. Barclays PLC grew its stake in shares of Dianthus Therapeutics by 390.5% during the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock valued at $1,141,000 after buying an additional 33,185 shares during the last quarter. HighVista Strategies LLC bought a new position in shares of Dianthus Therapeutics during the third quarter valued at about $542,000. State Street Corp grew its stake in shares of Dianthus Therapeutics by 101.4% during the third quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after buying an additional 413,425 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Dianthus Therapeutics by 142.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock valued at $4,543,000 after buying an additional 97,362 shares during the last quarter. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH opened at $21.33 on Wednesday. The company has a market cap of $631.30 million, a P/E ratio of -8.53 and a beta of 1.82. The stock’s fifty day moving average price is $22.54 and its two-hundred day moving average price is $24.81. Dianthus Therapeutics has a 1 year low of $18.13 and a 1 year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.04. The firm had revenue of $1.33 million for the quarter, compared to analysts’ expectations of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.